BioLife shareholders will receive $11.25 ⁠in cash and 0.1442 shares of Repligen for each share, valuing ⁠the cell therapy tools supplier at $31 per share — a premium of about 6.2% to BioLife's last ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.

Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to ...

CEO Roderick de Greef highlighted a strong start to 2025, with total revenue growing 30% year-over-year and cell processing revenue increasing by 33%. He emphasized the company’s focus on strategic ...

BioLife Solutions is headquartered in Bothell, WA. BioLife Solutions manufactures and markets bioproduction tools and services for the cell and gene therapy (CGT) industry. The stock currently trades ...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems ...

The MarketWatch News Department was not involved in the creation of this content. BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier ...